期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Programmed death 1 (PD-1) and ligand (PD-L1) inhibitors in head and neck squamous cell carcinoma: A meta-analysis
1
作者 Dylan A.Levy Jaimin J.Patel +7 位作者 Shaun A.Nguyen W.Nicholas Jungbauer David M.Neskey Ezra E.W.Cohen Chrystal M.Paulos John A.Kaczmar Hannah M.Knochelmann Terry A.Day 《World Journal of Otorhinolaryngology-Head and Neck Surgery》 2022年第3期177-186,共10页
Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in H... Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19,P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted. 展开更多
关键词 ANTIBODIES disease progression head and neck neoplasms HUMANIZED META-ANALYSIS MONOCLONAL squamous cell carcinoma of the neck
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部